Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to expect from LLY's Q1 results.

Mikhail Irzak is a marketing strategist and investor with expertise in business and culture. Discover his career across ...